Monoclonal antibody treatment for ulcerative colitis twice as effective as placebo, study shows
Of patients with ulcerative colitis who received the monoclonal antibody mirikizumab, 24% were in remission at the end of the trial period, compared with 13% who received placebo.
Patients received the treatment intravenously every 4 weeks for 12 weeks
Shutterstock.com
The results of two phase 3 trials of the monoclonal antibody mirikizumab have shown that the drug is better than placebo at inducing and maintaining remission in adults with moderately to severely active ulcerative colitis.
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
